Home› Future Meds›Aleniglipron
⚗️ Phase 2 💊 No Food Restrictions Structure Therapeutics · Daily pill

Aleniglipron

GSBR-1290 · Oral GLP-1 · Est. Phase 3: Late 2026

A once-daily GLP-1 pill with no food or water restrictions, take it any time. Phase 2 showed up to 16.3% placebo-adjusted weight loss, matching injectable-level results without the empty stomach rule.

💊
Phase 2 Loss
16.3%*
Est. Phase 3
Late 2026
Overview How It Works Trial Data Timeline Who It's For Compare FAQ
At a Glance

Aleniglipron by the Numbers

Phase 2 Weight Loss
Up to 16.3%*
Placebo-adjusted · ACCESS II trial
Form & Schedule
Daily Pill
Taken once a day, any time
Mechanism
Oral GLP-1
Small molecule, not a peptide
Food Restriction
None
Take it any time of day
Current Stage
Phase 2 Complete
Phase 3 planned late 2026
Developer
Structure Tx
Structure Therapeutics (GPCR)

*Placebo-adjusted means the drug's effect after subtracting what the placebo group lost. Actual total weight loss in the ACCESS II trial was approximately 20-22% from baseline at the 180mg dose.

Plain English

What makes Aleniglipron different from other oral GLP-1 drugs?

It's a small molecule pill, not a peptide, so your body absorbs it without needing an empty stomach. There's already one FDA-approved oral GLP-1 pill: Foundayo (orforglipron). But Aleniglipron takes a different approach that solves a real problem most oral GLP-1 drugs have.

✅
The big advantage: no food restrictions
Most oral GLP-1 drugs that came before aleniglipron had a catch: you had to take them on an empty stomach with a full glass of water, then wait 30-60 minutes before eating. For many people, this was a real daily hassle. Aleniglipron is a small molecule, it's structured differently from peptide-based drugs and is absorbed by your body without those restrictions. Take it with your coffee, after lunch, whenever. No planning required.
🔬
Why the chemistry matters
GLP-1 is actually a protein fragment (peptide), and peptides are fragile, stomach acid destroys them, which is why Wegovy has to be injected. Drug companies found ways to make some peptide-based pills (like oral semaglutide), but they require very specific absorption conditions. Aleniglipron is built as a small molecule from scratch, it's completely stable through digestion, absorbed reliably, and doesn't need special conditions to work.
1

You take one pill a day

Swallow once daily at whatever time works for your routine. No empty stomach required. Trials tested doses of 120mg and 180mg. The dose would be titrated gradually when starting treatment, same as injectable GLP-1 drugs.

2

It activates GLP-1 receptors in your gut and brain

GLP-1 receptors regulate hunger, fullness, and how fast your stomach empties. Activating them tells your brain you're full faster, makes you less interested in food, and slows digestion so you stay satisfied longer.

3

Weight drops gradually without injections

Trials showed no weight loss plateau through 44 weeks, weight continued to trend downward without leveling off. This is a promising signal that higher doses or longer treatment may produce even stronger results in Phase 3.

Clinical Evidence

What the Phase 2 Trials Showed

Phase 2b ACCESS: 11.3% placebo-adjusted at 36 weeks. ACCESS II: up to 16.3% at 44 weeks. Structure Therapeutics ran two Phase 2 trials, the ACCESS study and the ACCESS II study, testing different doses over different time periods. Both produced strong results, with higher doses and longer duration showing progressively better weight loss.

11.3%
Placebo-adjusted weight loss
120mg dose · 36 weeks · ACCESS trial
16.3%
Placebo-adjusted weight loss
180mg dose · 44 weeks · ACCESS II
No plateau
Weight still dropping at 44 weeks
Suggests potential for even more in longer trials
📋
What "placebo-adjusted" means: In the ACCESS II trial, the placebo group also lost some weight (due to lifestyle changes during the trial). Aleniglipron patients at 180mg lost about 20-22% from their starting weight in total. The 16.3% figure is the drug's effect after subtracting what the placebo group lost, this is the standard scientific way to measure a drug's actual contribution. Either way, it's a strong result for a daily pill, comparable to injectable drugs in earlier-stage trials.
Where Things Stand

Aleniglipron's Road to Approval

Phase 2 complete. Phase 3 expected to start late 2026. Approval likely 2029-2030. Aleniglipron is earlier in the process than CagriSema or Retatrutide, but the Phase 2 results were strong enough that Structure Therapeutics is moving quickly toward a Phase 3 design meeting with the FDA.

✓ Done
Phase 1, Is it safe?
Early safety testing confirmed aleniglipron was safe and well-tolerated at multiple doses, with a side-effect profile consistent with the GLP-1 drug class.
✓ Done
Phase 2a, Does it work?
The 12-week Phase 2a trial confirmed meaningful weight loss with the 120mg dose, 6.2% placebo-adjusted at 12 weeks. Enough to justify advancing to larger trials.
✓ Done
Phase 2b ACCESS, Longer trial
36-week trial confirmed 11.3% placebo-adjusted weight loss at 120mg. Strong safety profile, no weight plateau, off-target safety profile was clean.
✓ Done
Phase 2 ACCESS II, Higher doses
Exploring 180mg and 240mg over 44 weeks produced up to 16.3% placebo-adjusted weight loss with no plateau. Published March 2026, described as "injectable-like efficacy" for an oral GLP-1.
● Happening Now
End-of-Phase 2 FDA Meeting
Structure Therapeutics is meeting with the FDA in Q2 2026 to align on the Phase 3 design, what endpoints to measure, how many patients are needed, and how long the trials should run.
Up Next
Phase 3 testing
Phase 3 trials expected to launch in the second half of 2026. These will likely run 52-72 weeks and enroll thousands of patients. This is the final hurdle before FDA submission.
Future
FDA Decision
If Phase 3 succeeds, an FDA submission could happen around 2028, with a decision possible in 2029-2030. That's still several years away, but the science to get there looks strong.
Why This Drug Matters
★Every approved oral GLP-1 pill today has a catch, food restrictions, timing requirements, or lower efficacy. Aleniglipron is trying to be the first one that works on injection-level results without any of those trade-offs.
★A significant portion of people who would benefit from GLP-1 treatment don't want weekly injections. A highly effective pill with no restrictions could open access to a much larger group.
ℹThere's still a lot left to prove. Phase 2 is promising, but Phase 3 with thousands of patients will determine whether the results hold at scale.

"The problem with earlier oral GLP-1s wasn't the mechanism, it was getting the drug to absorb reliably. Aleniglipron takes a different approach to that and the early absorption data looks more consistent. That's the thing to watch."

Dr. Jeremy Bleicher, DO, MPH

Dr. Jeremy Bleicher, DO, MPH

Endocrinologist · Diabetes & Metabolic Health

Is It Right for You?

Who Aleniglipron Is, and Isn't, For

Best fit for people who want the efficacy of injectable GLP-1 drugs but strongly prefer a pill. Aleniglipron is years away from approval, but it's shaping up to be the most compelling option for people who want strong weight loss results from a pill, without the daily scheduling hassle of current oral options.

✅ Likely a strong fit

  • People who want GLP-1 efficacy but won't or can't do weekly injections
  • Anyone who tried oral semaglutide (Rybelsus) and found the food restriction inconvenient
  • People with a BMI of 30+ or 27+ with a weight-related condition
  • Those who prefer a daily pill that fits naturally into any routine
  • People willing to wait, if Phase 3 succeeds, aleniglipron could become the top oral option in its class

⚠️ Things to consider

  • Still 3-4 years from approval, if you need treatment now, current options like Foundayo or Wegovy are available
  • Phase 2 results are very promising but Phase 3 could still surprise, larger trials sometimes produce more conservative numbers
  • GI side effects (nausea, diarrhea) are expected with any GLP-1 drug, including this one
  • Cost and insurance coverage are unknown at this stage
Side by Side

How Aleniglipron Compares to Other Oral Options

How it stacks up against current and future oral weight loss medications.

Drug Weight Loss Form Food Restriction Status
💊Aleniglipron
You're here		 16%* (Ph2) Daily pill None ✓ Phase 2
💊Foundayo 12.4% Daily pill None ✓ ✓ Approved
💊Oral Wegovy 15% Daily pill Empty stomach ✓ Approved
💉Wegovy 15% Weekly injection None ✓ ✓ Approved
💊Rybelsus 5-10% Daily pill Empty stomach ✓ Approved

*Placebo-adjusted. Total weight loss from baseline in ACCESS II was approximately 20-22% at the 180mg dose. Phase 2 and Phase 3 data are not directly comparable to each other.

Common Questions

Frequently Asked Questions

Aleniglipron activates the same GLP-1 receptors as Wegovy and Ozempic, but it's built as a small molecule rather than a peptide. That distinction matters practically: peptide-based oral drugs (like oral semaglutide) are fragile in digestion and require you to take them on an empty stomach with very specific timing. Small molecule drugs like aleniglipron are stable, absorbed reliably, and require no food restrictions. The goal is injectable-level weight loss in a pill you can take any time of day.
In the Phase 2b ACCESS trial (36 weeks, 120mg dose), aleniglipron produced 11.3% placebo-adjusted weight loss. In the Phase 2 ACCESS II trial (44 weeks, 180mg dose), it produced 16.3% placebo-adjusted weight loss. The total weight lost from baseline in ACCESS II was approximately 20-22%, the placebo-adjusted number removes weight lost by the control group and isolates the drug's actual effect. One point worth flagging, weight was still declining at 44 weeks with no signs of plateau.
No, and this is one of the most important things about it. Oral semaglutide (sold as Rybelsus for diabetes) requires you to take it first thing in the morning on an empty stomach with only 4oz of water, then wait 30 minutes before eating or drinking anything else. Aleniglipron has no such restriction. You can take it any time of day, with or without food. This is because aleniglipron is a small molecule drug, not a peptide, so it doesn't need specific absorption conditions.
Phase 3 trials are expected to launch in the second half of 2026, following an End-of-Phase 2 meeting with the FDA in Q2 2026. Phase 3 trials typically run 1-2 years. If Phase 3 succeeds, an FDA submission could happen around 2028, with a potential approval around 2029-2030. There's still significant work and uncertainty ahead, but the Phase 2 results have been consistently strong.
Both are non-peptide small molecule oral GLP-1 drugs with no food restrictions. Foundayo (orforglipron) is FDA approved and available now, with Phase 3 data showing 12.4% weight loss. Aleniglipron's Phase 2 data showed up to 16.3% placebo-adjusted weight loss, and its Phase 2 ACCESS II study results led some researchers to describe it as having "injectable-like efficacy", though Phase 3 comparisons won't be available for years. Both represent a meaningful step forward from oral semaglutide in terms of convenience.
Side effects in Phase 2 were consistent with the GLP-1 drug class: primarily gastrointestinal effects including nausea, diarrhea, and constipation, especially during the dose-escalation phase. Structure Therapeutics reported an "off-target safety profile" that was clean, meaning no unexpected organ effects or safety signals beyond what's typical for GLP-1 drugs. The discontinuation rate due to adverse events was about 10.4% in the Phase 2b ACCESS trial. Full Phase 3 safety data won't be available until after those trials complete.
Dr. Jeremy Bleicher, DO, MPH
Medically Reviewed by
Dr. Bleicher
Endocrinologist
Keep Exploring

Related Medications

💊
Foundayo
Oral GLP-1 · FDA Approved
12.4% weight loss
💊
Rybelsus
Oral Dual Agonist · Phase 1
Very early stage
💉
Retatrutide
Triple Agonist · Phase 3
5-10% weight loss (Ph2)